Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research note released on Sunday morning.

CAPR has been the subject of a number of other research reports. Roth Capital boosted their price objective on Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. UBS Group set a $50.00 target price on Capricor Therapeutics in a research note on Monday, December 15th. B. Riley reissued a “buy” rating and set a $50.00 price target (up previously from $21.00) on shares of Capricor Therapeutics in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capricor Therapeutics in a report on Monday, December 29th. Finally, Oppenheimer lifted their price objective on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Stock Up 1.1%

Shares of NASDAQ:CAPR opened at $24.79 on Friday. The company has a market cap of $1.13 billion, a PE ratio of -13.77 and a beta of 0.22. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The firm has a 50-day simple moving average of $18.69 and a 200 day simple moving average of $11.27.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.54). As a group, research analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its stake in shares of Capricor Therapeutics by 39.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares during the period. KLP Kapitalforvaltning AS raised its holdings in Capricor Therapeutics by 65.2% during the second quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 4,300 shares in the last quarter. Geode Capital Management LLC lifted its position in Capricor Therapeutics by 6.8% in the second quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after purchasing an additional 61,701 shares during the period. HBK Sorce Advisory LLC lifted its position in Capricor Therapeutics by 33.7% in the third quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock worth $1,141,000 after purchasing an additional 42,951 shares during the period. Finally, Rhumbline Advisers boosted its stake in Capricor Therapeutics by 8.1% during the 1st quarter. Rhumbline Advisers now owns 49,814 shares of the biotechnology company’s stock valued at $473,000 after purchasing an additional 3,731 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.